Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Biotech Stocks with Huge Upside Potential.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,690,221 | $197,130,475 | +22% | 8.03% |
| 2. | Partner Fund Management Christopher Medlock James | 556,545 | $64,909,843 | +20% | 4.71% |
| 3. | D E Shaw D. E. Shaw | 547,665 | $63,874,169 | +2592% | 0.06% |
| 4. | GLG Partners Noam Gottesman | 513,221 | $59,856,965 | +215% | 0.15% |
| 5. | OrbiMed Advisors Samuel Isaly | 386,700 | $45,100,821 | 1.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.30 | 3,950 | $147,350.01 | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | $4,998.40 | 142 | 2021-11-18 | Filing | |
| $34.30 | 145 | $4,973.50 | 145 | 2021-11-18 | Filing | |
| $35.43 | 141 | $4,995.63 | 201 | 2021-11-18 | Filing | |
| $35.50 | 527 | $18,708.50 | 41,789 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $100.12 | 6,014 | $602,121.68 | 0 | 2025-06-23 | Filing | |
| $102.47 | 7,500 | $768,525.00 | 0 | 2025-06-20 | Filing | |
| $100.90 | 7,500 | $756,750.00 | 0 | 2025-06-18 | Filing | |
| $100.26 | 7,500 | $751,950.00 | 0 | 2025-06-17 | Filing | |
| $102.42 | 7,500 | $768,150.00 | 0 | 2025-06-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,876,942 | $452,167,746 | 0.01% | |
| 2. | 3,524,411 | $411,052,056 | 0.01% | |
| 3. | 2,922,729 | $340,877,883 | 5.21% | |
| 4. | 1,247,231 | $145,464,570 | 0.01% | |
| 5. | 976,260 | $113,861,000 | 0.15% |
News See All
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT
Purohit’s continued optimism is primarily driven by the strong commercial performance of Auvelity, the company’s treatment for major depressive disorder (MDD).
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast. At this time all participants are in a listen-only mode.
10 Best Performing Growth Stocks in 2025
Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector.
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call Transcript February 18, 2025Axsome Therapeutics, Inc. misses on earnings expectations.
Why Axsome Therapeutics (AXSM) Is Advancing Today
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from $105.
Billionaire Hedge Funds
